BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, December 27, 2024
Breaking News: Holiday special – 25% off BioWorld subscriptions
See today's BioWorld Science
Home
» BB-201, a potent first-in-class anti-Her2/anti-Trop2 bispecific ADC candidate
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
BB-201, a potent first-in-class anti-Her2/anti-Trop2 bispecific ADC candidate
Nov. 19, 2024
No Comments
Researchers from Bright Biologics LLC presented the discovery and preclinical characterization of a novel bispecific anti-Her2/anti-Trop2 antibody-drug conjugate (ADC), BB-201.
BioWorld Science
Conferences
Society for Immunotherapy of Cancer
Cancer
Antibody-drug conjugate
